Peer review reports
From: Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer
Original Submission | ||
---|---|---|
29 Jun 2015 | Submitted | Original manuscript |
17 Aug 2015 | Reviewed | Reviewer Report - Vimla Band |
11 Dec 2015 | Reviewed | Reviewer Report - SHEVDE SAMANT |
22 Mar 2016 | Author responded | Author comments - Marc Becker |
Resubmission - Version 2 | ||
22 Mar 2016 | Submitted | Manuscript version 2 |
13 Apr 2016 | Reviewed | Reviewer Report - Vimla Band |
3 May 2016 | Reviewed | Reviewer Report - Gargi Ghosal |
2 Jul 2016 | Author responded | Author comments - Marc Becker |
Resubmission - Version 3 | ||
2 Jul 2016 | Submitted | Manuscript version 3 |
20 Jul 2016 | Reviewed | Reviewer Report - Gargi Ghosal |
21 Jul 2016 | Author responded | Author comments - Marc Becker |
Resubmission - Version 4 | ||
21 Jul 2016 | Submitted | Manuscript version 4 |
Publishing | ||
7 Oct 2016 | Editorially accepted | |
20 Oct 2016 | Article published | 10.1186/s12885-016-2847-3 |